Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 19Burkitt Lymphoma 16Lymphoma, Large B-Cell, Diffuse 11Neuroblastoma 7Lymphoma, Follicular 7Lymphoma, B-Cell 7Leukemia, Biphenotypic, Acute 7Rhabdomyosarcoma 6Lymphoma, T-Cell, Peripheral 6Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 5Sarcoma, Ewing 4Lymphoma 4Retinoblastoma 3Recurrence 3Precursor B-Cell Lymphoblastic Leukemia-Lymphoma 3Osteosarcoma 3Medulloblastoma 3Lymphoma, T-Cell 3Lymphoma, Non-Hodgkin 3Wilms Tumor 2Sarcoma 2Plasmablastic Lymphoma 2Lymphoma, B-Cell, Marginal Zone 2Leukemia, B-Cell 2Hodgkin Disease 2Ganglioneuroblastoma 2Blastic Plasmacytoid Dendritic Cell Neoplasm 2Stage I Mixed Cell Type Kidney Wilms Tumor 1Rhabdomyosarcoma, Embryonal 1Rhabdoid Tumor 1

Interventions

prednylidene 1etoposide phosphate 1deltacortene 1Vincristine 1Vinblastine 1Specimen Handling 1Procarbazine 1Prednisone 1Prednisolone 1Nivolumab 1Methylprednisolone 1Magnetic Resonance Spectroscopy 1Fluorodeoxyglucose F18 1Etoposide 1Doxorubicin 1Dacarbazine 1Cyclophosphamide 1Brentuximab Vedotin 1Bleomycin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8 × Vincristine × Clear all
NCT05675410 2026-06-03

A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

National Cancer Institute (NCI)

Phase 3 Recruiting
1,875 enrolled
Lymphoid

Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡